Skip to main content
SpringerLink
Log in

Factors associated with transfusion requirements during treatment for acute myelogenous leukemia

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Summary

Supportive care is a prerequisite for intensive chemotherapy in leukemic patients. Little has been published about quantitative aspects of red blood cell and platelet transfusions. We evaluated transfusion requirements and factors associated with observed differences in 206 patients undergoing initial induction consolidation chemotherapy for newly diagnosed acute myelogenous leukemia. All patients were treated during a 5-year period in 12 hospitals on a common protocol of the Swiss Study Group for Clinical Cancer Research (SAKK). Protocol 30/85 comprises a double induction and one course of consolidation. Of 206 registered patients, 199 were evaluable; 118 of 199 (59%) patients entered completed all three cycles of chemotherapy. These 118 patients received a median (range) of 18 (3–44) units of red blood cells and 12 (2–61) platelet transfusions during 112 (70–129) days of hospitalization. Patients with a hemoglobin >10g/l, platelets >100×109/l, and white blood cell counts <5×109/l at diagnosis received fewer transfusions than patients with less favorable blood counts during the first cycle of chemotherapy (p<0.05). Patients with FAB subtype M3 received more platelet transfusions during the first cycle. Female patients received more platelet transfusions than male patients. In multivariate analyses the participating center was the most important single factor associated with the number of red cell and platelet concentrates given per patient and cycle (p<0.05), the number of days in hospital (p<0.05), and the risk of premature withdrawal from the study. These data define factors associated with transfusion requirements in patients treated for newly diagnosed AML. They include severity and subtype of disease at diagnosis, age and sex of the patients, and the participating institution. Results suggest that medical decision-making varies from center to center. The participating institution is strongly associated with differences in transfusion requirements, hospitalization time, and premature withdrawal from study. Leukemia trials tend to focus on the prospective evaluation of chemotherapy or growth factors. Our results suggest that other variables, such as management strategies, should be included for prospective analysis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rohatiner AZS, Lister TA (1990) The treatment of acute myelogenous leukemia. In: Henderson E, Lister TA (eds) Leukemia. WB Saunders, Philadelphia, p 485

    Google Scholar 

  2. Buechner T, Hiddemann W (1990) Treatment strategies in acute myeloid leukemia. Blut 60:61

    PubMed  Google Scholar 

  3. Stone RM, Mayer RJ (1993) Treatment of the newly diagnosed adult with de novo AML. Hematol Oncol Clin North Am (in press)

  4. Sauter C, Berchtold W, Fopp M, Gratwohl A, Imbach P, Maurice P, Tschopp L, von Fliedner V (1984) Acute myelogenous leukemia: maintenance chemotherapy after early consolidation treatment does not prolong survival. Lancet 1:379

    PubMed  Google Scholar 

  5. Zittoun R, Jehn U, Fière D, Haanen C, Löwenberg B, Willemze R (1989) Alternating v repeated postremission treatment in adult acute myelogenous leukemia. A randomized phase-3 study (AML 6) of the EORTC Leukemia Cooperative Group. Blood 73:896

    PubMed  Google Scholar 

  6. Berman E, Heller G, Santorsa J, McKenzie S, Gee T, Kempin S (1991) Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 77:1666

    PubMed  Google Scholar 

  7. Philips GL, Reece DE, Shepherd JD, Barnett MJ, Brown RA, Frei-Lahr DA (1991) High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults. Blood 77:1429

    PubMed  Google Scholar 

  8. Gmür J, Burger J, Schanz U, Fehr J, Schaffner A (1991) Safety of stringent prophylactic platelet transfusion policy for patients with acute leukemia. Lancet 338:1223

    PubMed  Google Scholar 

  9. Estey E, Thall PF, Kantarjian H, O'Brien S, Koller CA, Beran M (1992) Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF. Blood 79:2246

    PubMed  Google Scholar 

  10. Tilly H, Castaigne S, Bordessoule D, Casassus P, Le Prisé PY, Tertian G (1990) Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 8:272

    PubMed  Google Scholar 

  11. Johnson PRE, Liu Yin JA (1993) Clinical annotation: acute myeloid leukemia in the elderly — biology and treatment. Br J Haematol 83:1

    PubMed  Google Scholar 

  12. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C (1985) Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 103:620

    PubMed  Google Scholar 

  13. Fopp M, Schatzmann E, Fey MF, Gmuer J, Gratwohl A, Jacky E, Schmid L, Tichelli A, Tschopp L, von Fliedner V (1993) Randomized trial of post-remission high-dose versus standard-dose cytosine arabinoside in adult acute myeloid leukemia. Proc ASCO (1993) 12:304

    Google Scholar 

  14. Kruskal WH, Wallis WA (1952) Use of ranks in one criterion variance analysis. J Am Stat Assoc 47:587

    Google Scholar 

  15. Warrell RP, Frankel SR, Miller WH jr, Scheinberg DA, Itri LM, Hittelman WN (1991) Differentiation therapy of acute promyelocytic leukemia with tretinoin. N Engl J Med 324:1385

    PubMed  Google Scholar 

  16. McCullough J, Steeper TA, Connelly DP, Jackson B, Huntington S, Scott EP (1988) Platelet utilization in a university hospital. JAMA 259:2414

    PubMed  Google Scholar 

  17. Mozes B, Epstein M, Ben-Bassat I, Modan B, Halkin H (1989) Evaluation of the appropriateness of blood and blood product transfusions using preset criteria. Transfusion 29:473

    PubMed  Google Scholar 

  18. Coffin C, Matz K, Rich E (1989) Algorithms for evaluating the appropriateness of blood transfusions. Transfusions 29:298

    Google Scholar 

  19. Bowden RA, Sayers M, Flournoy N, Newton B, Banaji M, Donnall Thomas E (1986) Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med 314:1006

    PubMed  Google Scholar 

  20. Dauriac C, Le Berre C, Lamy T, Genetet B, Le Prise PY (1993) Review of 6 years of CMV negative transfusions before and after allogeneic BMT. Abstract, EBMT Meeting, Garmisch-Partenkirchen, 1993

  21. Berman E, Little C, Gee T, O'Reilly R, Clarkson B (1992) Reasons that patients with acute myelogenous leukemia do not undergo allogeneic bone marrow transplantation. N Engl J Med 326:156

    PubMed  Google Scholar 

  22. Ljungman P, de Witte T, Verdonck L, Gahrton G, Freyçon F, Gravett P, McCann S, Morgenstern HG, Nikoskelainen J, Powles R, Proctor SJ, Volin L, Zwaan F, Gratwohl A (1993) Bone marrow transplantation for acute myeloblastic leukemia: an EBMT Leukemia Working Party prospective analysis for HLA-typing. Br J Haematol 84:61–66

    PubMed  Google Scholar 

  23. Horowitz M, Przepiorka D, Champlin RE, Gale RP, Gratwohl A, Herzig RH, Prentice HG, Rimm AA, Ringden O, Bortin MM (1992) Should HLA-identical sibling bone marrow transplants for leukemia be restricted to large centers? Blood 79:2771

    PubMed  Google Scholar 

  24. Laffel GL, Barnett AI, Finkelstein S, Kaye MP (1992) The relation between experience and outcome in heart transplantation. N Eng J Med 327:1220

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Kantonsspital Basel, Berne, Switzerland

    G. Favre, A. Tichelli & A. Gratwohl

  2. Kantonsspital St. Gallen, Berne, Switzerland

    M. Fopp

  3. University Hospital Zurich, Berne, Switzerland

    J. Gmür

  4. Inselspital Berne, Berne, Switzerland

    M. F. Fey & A. Tobler

  5. Swiss Group for Clinical Cancer Research (SAKK), Berne, Switzerland

    E. Schatzmann

Authors
  1. G. Favre
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Fopp
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Gmür
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Tichelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. F. Fey
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Tobler
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. E. Schatzmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. Gratwohl
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This work was supported by an educational grant of Vestar Inc., San Dimas, CA, USA

For the Working Party Leukemia of the Swiss Group for Clinical Cancer Research (SAKK)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Favre, G., Fopp, M., Gmür, J. et al. Factors associated with transfusion requirements during treatment for acute myelogenous leukemia. Ann Hematol 67, 153–160 (1993). https://doi.org/10.1007/BF01695861

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01695861

Keywords

Search

Navigation